These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26124167)

  • 1. In vitro study of the variable effects of proton pump inhibitors on voriconazole.
    Niece KL; Boyd NK; Akers KS
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5548-54. PubMed ID: 26124167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
    Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
    Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
    Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereoselective disposition of proton pump inhibitors.
    Andersson T; Weidolf L
    Clin Drug Investig; 2008; 28(5):263-79. PubMed ID: 18407713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations.
    Blanco Dorado S; Maroñas Amigo O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Br J Clin Pharmacol; 2020 Aug; 86(8):1661-1666. PubMed ID: 32110830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole.
    Qi F; Zhu L; Li N; Ge T; Xu G; Liao S
    Int J Antimicrob Agents; 2017 Apr; 49(4):403-409. PubMed ID: 28159656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of proton pump inhibitors in children.
    Litalien C; Théorêt Y; Faure C
    Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents.
    Robinson M
    Eur J Gastroenterol Hepatol; 2001 May; 13 Suppl 1():S43-7. PubMed ID: 11430508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of proton pump inhibitors on cytochrome P450 activity assessed by
    Rocco A; Compare D; Sgamato C; Coccoli P; Chiodini P; Nardone G
    Aliment Pharmacol Ther; 2021 Mar; 53(5):608-615. PubMed ID: 33368499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The stereoselectivity of CYP2C19 on R- and S-isomers of proton pump inhibitors.
    Tian C; Zhu L; Yu D; Cao Z; Kang T; Zhu R
    Chem Biol Drug Des; 2014 May; 83(5):610-21. PubMed ID: 24350826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases.
    Huang Q; Liu Q; Yin T; Hu L; Ding H; Liu S; Jiang Y
    Eur J Clin Pharmacol; 2020 Jun; 76(6):833-842. PubMed ID: 32157329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
    J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Protonic pump inhibitors in kidney transplant patients: efficacy and safety].
    Cianciolo G; Feliciangeli G; Comai G; Stefoni S
    Minerva Urol Nefrol; 2007 Jun; 59(2):207-15. PubMed ID: 17571057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voriconazole-induced visual abnormality based on drug interaction between voriconazole and esomeprazole: A case report.
    Jiang Z; Li J; Zhao C; Chen J
    Int J Clin Pharmacol Ther; 2023 Oct; 61(10):460-465. PubMed ID: 37548457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature.
    Lopez JL; Tayek JA
    Drug Metab Dispos; 2016 Jan; 44(1):124-6. PubMed ID: 26502771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo.
    Yan M; Wu ZF; Tang D; Wang F; Xiao YW; Xu P; Zhang BK; Liu YP; Xiang DX; Banh HL
    Biomed Pharmacother; 2018 Dec; 108():60-64. PubMed ID: 30216801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
    Clark DW; Strandell J
    Eur J Clin Pharmacol; 2006 Jun; 62(6):473-9. PubMed ID: 16758264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection.
    McNicholl AG; Linares PM; Nyssen OP; Calvet X; Gisbert JP
    Aliment Pharmacol Ther; 2012 Sep; 36(5):414-25. PubMed ID: 22803691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.